Published in Medical Letter on the CDC and FDA, June 6th, 2010
The terms of the grant provide that up to $2.9 million of the funds awarded are to be used for the advancement of the Company's early-stage pipeline product candidates, including acetylcholinesterase (AChE), PRX-102, pr-antiTNF, and three undisclosed compounds in development. AChE, an anti-organophosphate nerve agent in development...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA